Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy.

Abstract

We present a patient receiving chronic anticoagulant treatment with recurrent and intractable gastrointestinal bleeding due to diffuse angiodysplasia. Following failure of previous medical and surgical treatment, and in light of the patient's need for chronic anticoagulation due to mechanical heart valve, she was treated with somatostatin analogue, octreotide s.c. 100 microg on alternate days for 28 months. Treatment significantly decreased the occurrence of bleeding episodes, the need for hospitalization and blood transfusion requirements despite continued anticoagulant therapy. Octreotide treatment should be considered in patients with refractory gastrointestinal bleeding due to angiodysplasia in particular in those who need anticoagulant treatment.

• Authors: M Blich, O Fruchter, S Edelstein, Y Edoute
• Journal: Scandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 38 Issue 7 Pg. 801-3 (Jul 2003) ISSN: 0036-5521 [Print] England
• PMID: 12889571 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticoagulants
• Hemostatics
• Warfarin
• Octreotide

Topics

• Aged
• Angiodysplasia (complications)
• Anticoagulants (adverse effects)
• Chronic Disease
• Drug Administration Schedule
• Female
• Gastrointestinal Hemorrhage (drug therapy, etiology)
• Hemostatics (administration & dosage, therapeutic use)
• Humans
• Octreotide (administration & dosage, therapeutic use)
• Warfarin (adverse effects)